In order to understand the outcomes associated with AdV infection in different subsets of allo-HCT recipients, it is important to understand the current approach to AdV detection and management. Due to the risks associated with AdV infection in allo-HCT recipients, guidelines have been developed to direct AdV screening and treatment practices, but the extent of adherence to these guidelines is unknown. 1, 9, 12, 13 The lack of consistently reported, contemporary, multicenter data on the current management practices for
AdV infection limits the understanding of incidence and outcomes reporting and the ability to generalize outcomes data between patient groups. This includes the ability to differentiate the presentation, progression, and outcomes of AdV infection in children and adults. The AdVance practice patterns survey aimed to document the current screening and treatment paradigms for AdV infection in adult and pediatric allo-HCT recipients in Europe.
| PATIENTS AND ME THODS
The practice pattern survey was a key part of the AdVance study, which was designed to collect retrospective data on the incidence and The practice patterns survey was completed by the lead AdVance investigator at each center. It included questions on the physician's experience, the annual number of transplants at the center, and the current clinical management of AdV infection in allo-HCT recipients at the centers. A copy of the survey is included in Appendix S1. Several questions asked about the screening and treatment approach for low-or high-risk patients, as defined locally.
The survey was distributed throughout 2017 and was completed on paper or directly via an electronic application within 2 weeks of receipt. Follow-up ensured that all centers responded. Results were summarized separately for physicians who reported that they manage pediatric patients (<18 years), and physicians who reported that they manage adult patients (≥18 years). As clinical practice was expected to differ significantly for pediatric and adult allo-HCT recipients, responses from the eight physicians who reported treating both pediatric and adult patients are not included. Data were compiled and analyzed by Analytica Laser using processes that adhered to good data management practices and data protection laws. All data management processes were conducted per standard operating procedures, ISO/IEC 27001/27002, and were CFR 21 part 11 compliant.
| RE SULTS
AdVance practice pattern surveys were completed throughout 2017. Twenty-eight physician respondents reported that they manage pediatric patients ( Fourteen physician respondents reported that they manage adult patients ( Table 1 ). The majority were hematology specialists (79%). These physicians had a median of 17 (IQR 14-25) years of experience managing allo-HCT recipients; 64% managed more than 50 allo-HCT recipients per year, and the median number of AdV infection cases managed per year was two (IQR 0-3).
Eight respondents reported that they manage both pediatric and adult patients. Data from these surveys were not part of this analysis.
| Physicians who manage pediatric patients

| Screening
Each of the physicians who manage pediatric patients reported that there was a routine screening practice for the detection of or just blood samples (39%). Stool samples are not commonly used alone for screening (14%; Figure 2 ).
| Pre-emptive treatment
Among the 28 physicians who manage pediatric patients, 89%
(25/28) utilize a pre-emptive approach to AdV infection after it is identified in a patient they perceive to be high-risk; 75% (21/28) utilize a pre-emptive approach to AdV infection after it is identified in a patient they perceive to be low-risk ( Figures 3 and 4 ).
Twenty-five physicians reported using a virologic threshold for the initiation of pre-emptive antiviral therapy. Among the 13/25
physicians who pre-emptively treat high-risk patients and reported an AdV viremia threshold above which they initiate therapy, the median pre-emptive treatment threshold was 1000 AdV copies/mL (IQR: 1000-5000). Just over half (52%; 13/25) of physicians consider pre-emptive treatment when a high-risk pediatric patient has qualitatively detectable AdV or where AdV viremia is <1000 copies/mL, but 44% (11/25) wait for AdV viremia to reach ≥1000 copies/mL.
Physicians reported waiting for higher levels of AdV viremia before initiating pre-emptive treatment in patients they felt to be at low risk vs those they felt to be at high risk. Among the 13/21 physicians who pre-emptively treat low-risk patients and reported an AdV viremia threshold above which they initiate therapy, the median threshold was 1500 copies/mL (IQR 1000-5000). Fifty-seven percent of physicians require AdV viremia ≥1000 copies/mL to initiate pre-emptive treatment, while 35% consider treatment at any detectable AdV viremia or for thresholds <1000 copies/mL.
When asked to indicate the types of pre-emptive treatment used, all physicians reported that they use off-label cidofovir for pre-emptive treatment in both high-and low-risk pediatric patients.
Other pre-emptive treatment options considered for high-risk patients were the investigational drug brincidofovir (11/25; 44%), cellbased therapy (9/25; 36%), and off-label ribavirin (3/25; 12%). Similar options were identified for low-risk patients: the investigational drug brincidofovir (8/21; 38%), cell-based therapy (3/21; 14%), and offlabel ribavirin (2/21; 10%).
| Treatment of symptomatic disease
Ninety-six percent of physicians reported that their center had a standard treatment regimen for AdV infection in pediatric allo-HCT patients. Although no treatments are indicated for AdV infection, when asked to rank their first-line treatments for symptomatic AdV disease, more than 85% of physicians picked intravenous off-label cidofovir as their first choice ( Table 2 ). The investigational drug brincidofovir was a first or second choice for 57% of physicians, followed by cell-based therapy and off-label ribavirin.
Ninety-six percent of physicians reported that there was a standard protocol for the use of intravenous cidofovir at their center. For F I G U R E 1 Routine screening practices for adenovirus in allogeneic hematopoietic stem cell transplant recipients typical pediatric patients, this most commonly consisted of a starting and maintenance dose of 5 mg/kg/wk (68% starting; 61% maintenance; others chose 1 mg/kg three times a wk; Table 2 ). 
| Physicians
| Pre-emptive treatment
A pre-emptive treatment approach to AdV infection was reported for high-risk patients by 29% (4/14) of physicians, and for low-risk patients by 14% (2/14) of physicians ( Figures 3 and 4) . Among those physicians who reported pre-emptive treatment, all reported use of off-label cidofovir therapy. Few physicians reported the use of quantitative AdV viremia thresholds for pre-emptive treatment initiation (Figures 3 and 4) .
| Treatment of symptomatic disease
Seventy-one percent of physicians who manage adult allo-HCT recipients reported their center had a standard treatment regimen for AdV infection in adult patients. Similar to physicians who manage pediatric patients, 93% of physicians who treat adult patients reported off-label cidofovir as their first-line treatment for symptomatic AdV disease (Table 2) . Off-label ribavirin (43%) and investigational brincidofovir (29%) were common second choices, followed by cell-based therapy.
Consistent with the responses from physicians who manage pediatric patients, 96% of physicians who manage adult patients reported that there was a standard protocol for intravenous cidofovir use at their center. For adult patients, this generally consisted of 5 mg/kg/wk as starting and maintenance dosages ( Table 2 ).
| D ISCUSS I ON
The AdVance practice patterns survey is the first to comprehensively summarize the current standard of care for AdV infection in allo-HCT recipients across multiple European transplant centers.
Findings suggest that AdV screening and treatment practices are It is widely reported that the incidence of AdV infection is higher among pediatric allo-HCT recipients than adult allo-HCT recipients. 7, 8, 14, 15 In many cases, the source of AdV infection is thought to be persistent AdV in the gastrointestinal tract. 16, 17 Differences in patient risk likely led to the divergent surveillance and treatment approaches we observed: 93% of treating physicians routinely screen all pediatric allo-HCT recipients for AdV infection in blood and/or stool, whereas 21% screen all adult allo-HCT recipients. Moreover, those who would not routinely screen all allo-HCT recipients commonly reported that they would screen those with well-described risk factors for AdV infection, such as GvHD, cord blood or haploidentical transplant, or T-cell depletion. Differences in screening practices for pediatric and adult allo-HCT recipients may impact the identification of AdV infection in these distinct patient groups, with the likely delays in diagnosing adult patients. Likewise, the routine surveillance in pediatric allo-HCT recipients could also contribute to the higher incidence of AdV infection. 4, 7, 18, 19 Although the definition of risk varies among previously published guidelines, a risk-based approach to screening has generally been supported. 
F I G U R E 3
Approach to pre-emptive treatment of adenovirus infection identified in allogeneic hematopoietic stem cell transplant recipients considered to be "high-risk"
Results from the AdVance practice patterns survey suggest that physicians most commonly choose blood, or blood and stool, as their sample of choice for AdV screening. AdV viremia is widely considered to be an indicator of potential disease dissemination, 4, 5, 20 and stool AdV positivity has been proposed in pediatric patients as an early predictor of viremia. 21 The latest position statement from the IDWP EBMT reinforces the idea that the gastrointestinal tract is a common source of latent AdV and recommends stool screening in pediatric allo-HCT recipients both before conditioning and alongside blood screening until lymphocyte reconstitution. 13 Survey responses showed that more than 75% of physicians who manage pediatric patients report pre-emptive AdV treatment for those considered to be at low or high risk, but this was the case for less than 30% of physicians who manage adult patients. The stated AdV treatment thresholds further confirmed that their readiness to treat was based on perceived risk (high or low). While ECIL-4 guidelines did not provide a threshold for pre-emptive treatment, the most recent position statement from the IDWP EBMT suggests that treatment should be considered for immunocompromised pediatric allo-HCT recipients when viremia reaches ≥1000 copies/mL or when AdV in stool is above 10 6 copies/g and is rapidly rising. perception of patient risk. AdV is known to be a potentially serious complication following allo-HCT, particularly in pediatric patients.
These perceptions appear to drive a more proactive screening and treatment approach in children than in adults. 
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TA B L E 2 First-line therapy for new cases of symptomatic adenovirus disease and standard protocols for the use of intravenous cidofovir Note that responses from physicians who manage pediatric patients and those who manage adult patients should not be directly compared.
